ベーチェット病およびシェーグレン症候群における難治性口腔潰瘍への分子状水素補助投与：T細胞マーカーおよび抗Ro抗体への影響を示す症例報告
A 67-year-old Taiwanese woman with concurrent Behçet's disease and primary Sjögren's syndrome experienced persistent recurrent oral ulcers and mucosal atrophy from 2018 onward. Standard regimens including hydroxychloroquine, colchicine, and monthly high-dose intravenous vitamin C with glutathione failed to prevent recurrence. Oral molecular hydrogen capsules were introduced in January 2024 as an adjunct to existing medications. Over subsequent months, mucosal bleeding diminished and serum anti-Ro antibody levels declined. Immunophenotyping demonstrated increases in naive T helper Fas-positive and cytotoxic T cell PD-1-positive subsets, consistent with immunomodulatory activity. No significant adverse events were recorded. By August 2025, oral ulcers had substantially resolved while systemic disease remained stable under maintenance with hydroxychloroquine, azathioprine, corticosteroid infusions, and continued hydrogen supplementation. These findings suggest that molecular hydrogen may exert both clinical and immunologic effects in autoimmune-related refractory mucosal disease.
Molecular hydrogen's antioxidant and immunomodulatory properties appear to shift T cell subsets, increasing naive T helper Fas-positive and cytotoxic PD-1-positive populations, which may suppress autoantibody (anti-Ro) production and reduce mucosal inflammation.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/41760342